Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M. Brioli A, et al. Among authors: fabisch c. Leukemia. 2024 May;38(5):1072-1080. doi: 10.1038/s41375-024-02204-y. Epub 2024 Mar 28. Leukemia. 2024. PMID: 38548962 Free PMC article.
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.
Hammersen J, Birndt S, Döhner K, Reuken P, Stallmach A, Sauerbrey P, La Rosée F, Pfirrmann M, Fabisch C, Weiss M, Träger K, Bremer H, Russo S, Illerhaus G, Drömann D, Schneider S, La Rosée P, Hochhaus A. Hammersen J, et al. Among authors: fabisch c. Leukemia. 2023 Sep;37(9):1879-1886. doi: 10.1038/s41375-023-01979-w. Epub 2023 Jul 28. Leukemia. 2023. PMID: 37507425 Free PMC article.
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
Schönfeld L, Rinke J, Hinze A, Nagel SN, Schäfer V, Schenk T, Fabisch C, Brümmendorf TH, Burchert A, le Coutre P, Krause SW, Saussele S, Safizadeh F, Pfirrmann M, Hochhaus A, Ernst T. Schönfeld L, et al. Among authors: fabisch c. Leukemia. 2022 Sep;36(9):2242-2249. doi: 10.1038/s41375-022-01648-4. Epub 2022 Jul 28. Leukemia. 2022. PMID: 35902731 Free PMC article.
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
Brioli A, Manz K, Pfirrmann M, Hänel M, Schwarzer AC, Prange-Krex G, Fabisch C, Knop S, Illmer T, Krammer-Steiner B, Hochhaus A, von Lilienfeld-Toal M, Mügge LO. Brioli A, et al. Among authors: fabisch c. J Cancer Res Clin Oncol. 2020 Mar;146(3):749-759. doi: 10.1007/s00432-019-03101-z. Epub 2019 Dec 2. J Cancer Res Clin Oncol. 2020. PMID: 31788741 Clinical Trial.
PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.
Drube J, Ernst T, Pfirrmann M, Albert BV, Drube S, Reich D, Kresinsky A, Halfter K, Sorio C, Fabisch C, Hochhaus A, Böhmer FD. Drube J, et al. Among authors: fabisch c. Oncotarget. 2018 Jan 15;9(10):9442-9455. doi: 10.18632/oncotarget.24253. eCollection 2018 Feb 6. Oncotarget. 2018. PMID: 29507701 Free PMC article.